脓毒血症的研究进展
Research Progress of Sepsis
DOI: 10.12677/ACM.2023.132366, PDF,   
作者: 王 晨, 张跃新*:新疆医科大学,新疆 乌鲁木齐;新疆医科大学第一附属医院感染中心,新疆 乌鲁木齐
关键词: 脓毒血症感染发病机制抗菌治疗Sepsis Infection Pathogenesis Antimicrobial Therapy
摘要: 脓毒血症(Sepsis)是宿主对感染的反应失调引起的危及生命的器官功能障碍,代表了从菌血症到感染性休克的一系列疾病严重程度。是机体感染后引起的一种全身性免疫反应,进展到后期可发展为脓毒血症休克、多器官衰竭甚至是死亡。脓毒血症发病率和死亡率较高,增加了基层医疗负担。脓毒血症的病因种类多,且个体化差异,如患者的性别、年龄、感染部位、感染来源及所患的基础疾病等,所导致的症状及预后也有所不同,因脓毒血症的病程发展迅速,目前尚无特殊治疗方法;其治疗策略主要为抗生素控制感染,支持对症治疗。本文主要围绕脓毒血症的诊断、发生机制以及治疗的研究进展进行综述,通过对国内外文献中脓毒血症的研究现状及进展的归纳,进行进一步的思考,以期为后续脓毒血症相关研究提供思路。
Abstract: Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection, representing a spectrum of disease severity from bacteremia to septic shock. It is a systemic im-mune response caused by infection, which can progress to septic shock, multiple organ failure and even death in the later stage. Sepsis has high morbidity and mortality, which increases the burden of primary medical care. There are many kinds of causes of sepsis, and individual differences, such as gender, age, site of infection, source of infection, and underlying diseases of patients, resulting in different symptoms and prognosis. Because the course of sepsis develops rapidly, there is no special treatment at present. The treatment strategy is mainly to control infection with antibiotics and support symptomatic treatment. This article mainly focuses on the diagnosis, pathogenesis and treatment of sepsis, and summarizes the research status and progress of sepsis in the domestic and foreign literature, in order to provide ideas for the follow-up research on sepsis.
文章引用:王晨, 张跃新. 脓毒血症的研究进展[J]. 临床医学进展, 2023, 13(2): 2588-2593. https://doi.org/10.12677/ACM.2023.132366

参考文献

[1] Timmermans, S. and Libert, C. (2018) Learning Lessons in Sepsis from the Children. Molecular Systems Biology, 14, e8335. [Google Scholar] [CrossRef] [PubMed]
[2] Majno, G. (1991) The Ancient Riddle of Sigma Eta Psi Iota Sigma (Sepsis). The Journal of Infectious Diseases, 163, 937-945. [Google Scholar] [CrossRef] [PubMed]
[3] Kumar, V. (2018) Targeting Macrophage Immunometabolism: Dawn in the Darkness of Sepsis. International Immunopharmacology, 58, 173-185. [Google Scholar] [CrossRef] [PubMed]
[4] Reinhart, K., Daniels, R., Kissoon, N., et al. (2017) Recognizing Sepsis as a Global Health Priority—A WHO Resolution. The New England Journal of Medicine, 377, 414-417. [Google Scholar] [CrossRef
[5] American College of Chest Physicians/Society of Critical Care Medi-cine Consensus Conference: Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis. Critical Care Medicine, 1992, 20, 864-874.[CrossRef
[6] Bone, R.C., Balk, R.A., Cerra, F.B., et al. (1992) Defi-nitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest, 101, 1644-1655. [Google Scholar] [CrossRef] [PubMed]
[7] Levy, M.M., Fink, M.P., Marshall, J.C., et al. (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Critical Care Medicine, 31, 1250-1256. [Google Scholar] [CrossRef
[8] Vincent, J.L., Opal, S.M., Marshall, J.C., et al. (2013) Sepsis Definitions: Time for Change. The Lancet, 381, 774-775. [Google Scholar] [CrossRef
[9] Balk, R.A. (2014) Systemic Inflammatory Response Syn-drome (SIRS): Where Did It Come from and Is It Still Relevant Today? Virulence, 5, 20-26. [Google Scholar] [CrossRef] [PubMed]
[10] Kaukonen, K.M., Bailey, M., Pilcher, D., et al. (2015) Systemic Inflamma-tory Response Syndrome Criteria in Defining Severe Sepsis. The New England Journal of Medicine, 372, 1629-1638. [Google Scholar] [CrossRef
[11] Huang, M., Cai, S. and Su, J. (2019) The Pathogenesis of Sepsis and Potential Therapeutic Targets. International Journal of Molecular Sciences, 20, 5376. [Google Scholar] [CrossRef] [PubMed]
[12] Takeuchi, O. and Akira, S. (2010) Pattern Recognition Receptors and Inflammation. Cell, 140, 805-820. [Google Scholar] [CrossRef] [PubMed]
[13] D’Elia, R.V., Harrison, K., Oyston, P.C., et al. (2013) Targeting the “Cytokine Storm” for Therapeutic Benefit. Clinical and Vaccine Immunology, 20, 319-327. [Google Scholar] [CrossRef
[14] Raymond, S.L., Holden, D.C., Mira, J.C., et al. (2017) Microbial Recognition and Danger Signals in Sepsis and Trauma. Biochimica et Biophysica Acta—Molecular Basis of Disease, 1863, 2564-2573. [Google Scholar] [CrossRef] [PubMed]
[15] Lamkanfi, M. (2011) Emerging Inflammasome Effector Mecha-nisms. Nature Reviews Immunology, 11, 213-220. [Google Scholar] [CrossRef] [PubMed]
[16] Kawai, T. and Akira, S. (2010) The Role of Pattern-Recognition Receptors in Innate Immunity: Update on Toll-Like Receptors. Nature Immunology, 11, 373-384. [Google Scholar] [CrossRef] [PubMed]
[17] Hagar, J.A., Powell, D.A., Aachoui, Y., et al. (2013) Cytoplasmic LPS Acti-vates Caspase-11: Implications in TLR4- Independent Endotoxic Shock. Science, 341, 1250-1253. [Google Scholar] [CrossRef] [PubMed]
[18] Deng,, M., Tang, Y., Li, W., et al. (2018) The Endotoxin Delivery Protein HMGB1 Mediates Caspase-11-Dependent Lethality in Sepsis. Immunity, 49, 740-753. [Google Scholar] [CrossRef] [PubMed]
[19] Efron, P.A., Martins, A., Minnich, D., et al. (2004) Characteri-zation of the Systemic Loss of Dendritic Cells in Murine Lymph Nodes during Polymicrobial Sepsis. The Journal of Immunology, 173, 3035-3043. [Google Scholar] [CrossRef] [PubMed]
[20] Cheng, S.C., Scicluna, B.P., Arts, R.J., et al. (2016) Broad De-fects in the Energy Metabolism of Leukocytes Underlie Immunoparalysis in Sepsis. Nature Immunology, 17, 406-413. [Google Scholar] [CrossRef] [PubMed]
[21] Ma, Y., Zhou, Y., Wu, F., et al. (2019) The Bidirectional Interactions between Inflammation and Coagulation in Fracture Hematoma. Tissue Engineering Part B: Reviews, 25, 46-54. [Google Scholar] [CrossRef] [PubMed]
[22] Biemond, B.J., Levi, M., Ten, C.H., et al. (1995) Plasminogen Ac-tivator and Plasminogen Activator Inhibitor I Release during Experimental Endotoxaemia in Chimpanzees: Effect of In-terventions in the Cytokine and Coagulation Cascades. Clinical Science (London), 88, 587-594. [Google Scholar] [CrossRef] [PubMed]
[23] Rocha, M., Herance, R., Rovira, S., et al. (2012) Mitochondrial Dysfunc-tion and Antioxidant Therapy in Sepsis. Infectious Disorders—Drug Targets, 12, 161-178. [Google Scholar] [CrossRef] [PubMed]
[24] Quoilin, C., Mouithys-Mickalad, A., Lecart, S., et al. (2014) Evidence of Oxidative Stress and Mitochondrial Respiratory Chain Dysfunction in an in Vitro Model of Sepsis-Induced Kidney Injury. Biochimica et Biophysica Acta, 1837, 1790-1800. [Google Scholar] [CrossRef] [PubMed]
[25] Hotchkiss, R.S., Swanson, P.E., Freeman, B.D., et al. (1999) Apoptotic Cell Death in Patients with Sepsis, Shock, and Multiple Organ Dysfunction. Critical Care Medicine, 27, 1230-1251. [Google Scholar] [CrossRef] [PubMed]
[26] Maurer, K., Reyes-Robles, T., Alonzo, F.R., et al. (2015) Autophagy Mediates Tolerance to Staphylococcus aureus Alpha-Toxin. Cell Host & Microbe, 17, 429-440. [Google Scholar] [CrossRef] [PubMed]
[27] Qiu, P., Liu, Y. and Zhang, J. (2019) Review: The Role and Mechanisms of Macrophage Autophagy in Sepsis. Inflammation, 42, 6-19. [Google Scholar] [CrossRef] [PubMed]
[28] Rhodes, A., Evans, L.E., Alhazzani, W., et al. (2017) Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Medicine, 43, 304-377. [Google Scholar] [CrossRef] [PubMed]
[29] Sterling, S.A., Miller, W.R., Pryor, J., et al. (2015) The Impact of Timing of Antibiotics on Outcomes in Severe Sepsis and Septic Shock: A Systematic Review and Meta-Analysis. Criti-cal Care Medicine, 43, 1907-1915. [Google Scholar] [CrossRef
[30] Salmeri, M., Sorbello, M.G., Mastrojeni, S., et al. (2016) Infections of Cardiovascular Implantable Electronic Devices: 14 Years of Experience in an Italian Hospital. Le Infezioni in Medicina, 24, 131-136.
[31] Shankar-Hari, M., Spencer, J., Sewell, W.A., et al. (2012) Bench-to-Bedside Review: Im-munoglobulin Therapy for Sepsis—Biological Plausibility from a Critical Care Perspective. Critical Care, 16, 206. [Google Scholar] [CrossRef] [PubMed]
[32] Alejandria, M.M., Lansang, M.A., Dans, L.F., et al. (2013) Intravenous Im-munoglobulin for Treating Sepsis, Severe Sepsis and Septic Shock. Cochrane Database of Systematic Reviews, 2013, D1090. [Google Scholar] [CrossRef
[33] Rossmann, F.S., Kropec, A., Laverde, D., et al. (2015) In Vitro and in Vivo Activity of Hyperimmune Globulin Preparations against Multiresistant Nosocomial Pathogens. Infection, 43, 169-175. [Google Scholar] [CrossRef] [PubMed]